Compare OMEX & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMEX | MNOV |
|---|---|---|
| Founded | 1986 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.6M | 69.4M |
| IPO Year | 2024 | 2004 |
| Metric | OMEX | MNOV |
|---|---|---|
| Price | $0.91 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | ★ 756.5K | 22.4K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $9,327.00 | ★ $2,360,807.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $180.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $0.74 | $1.17 |
| 52 Week High | $4.43 | $1.96 |
| Indicator | OMEX | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 35.21 | 33.07 |
| Support Level | $0.87 | $1.20 |
| Resistance Level | $1.72 | $1.32 |
| Average True Range (ATR) | 0.09 | 0.04 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 6.65 | 2.78 |
Odyssey Marine Exploration Inc is a deep-ocean exploration company. It discovers, validates, and develops high-value seafloor mineral resources and provides specialized mineral exploration, project development, and marine services to its clients. The company's subsea project portfolio contains multiple projects in various stages of development, such as the Phosagmex Project, a rich deposit of phosphate sands located seventy-ninety meters deep within the Mexican EEZ; two polymetallic nodule exploration license holders in the Cook Islands' EEZ; the Lihir Gold Project, a subsea area that contains several prospective gold exploration targets located in the Papua New Guinea Exclusive Economic Zone (EEZ); and others.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.